US Stem Cell, Inc. (OTCMKTS: USRM) Shares Spike Higher By 62% – Street Register

Shares of U.S. Stem Cell, Inc. (OTCMKTS: USRM) are surging early in the session today. The stock price is up over 62% on heavy volume. According to OTC Markets, the stock over the last 30 days trades about 15.6M shares per day, however; more than 43.5M shares have traded thus far. The stock price is currently trading around $0.19.

U.S. Stem Cell, Inc. (OTCMKTS: USRM) is a biotech company dedicated to expanding regenerative medicine. Weve seen shares rise significantly in 2017. However, that doesnt come without its fair share of volatility. Over the last 52-weeks the stock has traded in a range between $0.0016 to $0.40.

Nonetheless, we have not seen any news in U.S. Stem Cell, Inc. (OTCMKTS: USRM) to justify the move today. Based on Fridays close, the company had a market cap of around $697K. In addition, has a one star quantitative valuation from Morningstar.

About U.S. Stem Cell, Inc.

Founded in 1999, U.S Stem Cell, Inc. is committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the bodys own healing potential, we may be able to reverse damaged tissue to normal function. U.S. Stem Cells discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. U.S Stem Cell is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.

Most Recent Headline:

CSO Kristin Comella Publishes Paper on the Implantation of Stromal Vascular Fraction in Patients with Degenerative Disc Disease

SUNRISE, FL / ACCESSWIRE / January 23, 2017 / US STEM CELL, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to announce our newest publication by our Chief Scientific Officer, Kristin Comella.

Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease was published in the January volume of the Journal of Translational Medicine. The study focused on the implantation of stromal vascular fraction (SVF) in patients suffering from degenerative disc disease. Patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue from the abdomen. The fat was separated to isolate the SVF and the cells were delivered directly into the damaged discs. Patients were monitored for a period of 6 months post-treatment, noting considerable decreases in pain and increases in flexion. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/28086781.

Ms. Comellas previous paper, Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy, was released in the Journal of Translational Medicines June 2016 edition. Using the same procedure, chronic ischemic cardiomyopathy patients were evaluated after SVF injection and able to walk more than 80 additional meters 3 to 6 months after treatment. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/27255774.

At U.S. Stem Cell, Inc., we are committed to new technological advancements and therapies that give a renewed sense of hope to patients with degenerative diseases. SVF is the latest therapy in a long line of successful treatments we have pioneered. Ms. Comella plans to continue her work with SVF, which has consistently repeated its strong safety profile and success in treating patients.

Weve seen a tremendous amount of volatility in the biotech and medical space thus far this year. It will be interesting to see how politics play a role in stocks like USRM. If youd like to keep up with biotech stocks like USRM, make sure to sign up to our newsletter below. We make it quick and easy for our subscribers to stay on top of the markets. And yes, its free Which makes our membership affordable for everyone.

See the rest here:
US Stem Cell, Inc. (OTCMKTS: USRM) Shares Spike Higher By 62% - Street Register